title: Top topics in HCV research arena.
abstract: A significant improvement in the rate of eradication of Hepatitis C Virus Genotype 1 has been achieved with the addition of Boceprevir and Telaprevir to pegylated interferon and ribavirin. These two drugs are the heralds of a new wave of antivirals that will improve the efficacy of pegylated interferon or even will substitute this drug in interferon free combinations. The results of phase II studies in patients naïve to treatment seem to be very promising strongly supporting the possibility of a large success for a first line all oral antiviral combination in interferon naïve. However, data observed in interferon experienced patients are less exciting and probably more complex treatment regimens will be needed to treat this patients' population.
authors.affiliation: Infectious Diseases Unit AO Ospedale Niguarda Ca' Granda, 20162 Milano, Italy. massimopuoti@libero.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Puoti
authors.forename: Roberto
authors.initials: R
authors.lastname: Rossotti
authors.forename: Giovanna
authors.initials: G
authors.lastname: Travi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Orso
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Moioli
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans
chemical_list: D000998:Antiviral Agents